Research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 1.2 %
Titan Pharmaceuticals stock opened at $3.34 on Friday. The business has a 50 day moving average price of $3.67 and a two-hundred day moving average price of $4.83. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Consumer Discretionary Stocks Explained
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
